Pharmaceutical Congress China 29-30 March 2016

Produced by:

LifeSciences

29 - 30 March 2016 Grand Hyatt Shanghai

CHINA

Co-Located Events:

The leading event that brings togetherChina’s leading pharmaceuticalcompanies and industry in one place!

Li ChenCEO,Hua Medicine,China

Xian Ping LuCEO & CSO,Shenzhen

Chipscreen

Biosciences, China

Friedhelm BlobelCEO,SciClone

Pharmaceuticals,USA & China

Ming-Chu HsuChairman of theBoard & CEO,TaiGen

Biotechnology,Taiwan

Weikang TaoCEO, R&D Centre,Shanghai Hengrui

Medicine, China

Yin Xiang WangCEO & CSO,Betta

Pharmaceuticals,China

Ming-QiangZhangCorporate Vice-President, Research &Development,Amgen, China

Joan ShenVice President,Development HeadChina R&D and ScientificAffairs, Janssen

Pharmaceuticals,

Johnson & Johnson,China

Steffanie Lim-HoVice President,Ethics & Compliance,Lilly, China

Masood AhmedVice President,Regional ComplianceOfficerAsia & JPAC,Sanofi Group,Singapore

Associate Sponsor: Session Spotlight Sponsor:Bronze Sponsor:

International MarketingPartner:

CHINA

Li YanVice President, HeadUnit Physician,Oncology R&D,GlaxoSmithKline

Pharmaceuticals,USA

Latest Updates on China’sPharmaceutical regulation andmarket trends

Practical Case Studies on theGround in China

75+ renowned speakers fromthe pharmaceutical industry

1 shared exhibition room toshowcase latest technology andservices

4 days of expert knowledgesharing

TOP REASONSTO ATTEND

www.pharmaconchina.com

Shanghai Food & DrugAdministration (SFDA)

Taiwan Food & DrugAdministration (TFDA)

Keynote Regulator Sessions from:

Industry Experts Include:

Ye HuaSenior Vice President,Clinical Development andRegulatory Affairs,Hutchison

Medipharma, China

Optimizeyour Time & Money

with a Gold Pass- Full Access to

ALL Events is Possible!

Gold Sponsor:

Exhibitors:

9.00 R&D Market Opportunities & Challenges• Current drug development scenario in China vs. the West• How do you bring products to market quickly and cost effectively in China?• Can the local Chinese pharma companies sustain R&D innovation?• Encouraging innovation and healthy development of the pharmaceutical industry• What is the future of drug development in China?Moderator: Marrietta Wu, COO, Zai Laboratories, ChinaPanelists: Li Chen, CEO, Hua Medicine, China

Yin Xiang Wang, CEO & CSO, Zhejiang Beta Pharmaceuticals, ChinaFriedhelm Blobel, CEO, SciClone Pharmaceuticals, USA & ChinaMing-Chu Hsu, Chairman of the Board & CEO, TaiGen Biotechnology, TaiwanWeikang Tao, CEO, R&D Centre, Shanghai Hengrui Medicine, China

CHINA

REGISTER TODAY! +65 6508 2401 [email protected] www.pharmaconchina.com

CONFERENCE DAY ONE TUESDAY 29 MARCH 2016

8.00 Registration & Morning Coffee

8.50 Welcome Address from IBC Asia & Get to Know Your Peers

8.55 Chairperson’s Opening Remarks

KEY

NO

TE C

-LEV

EL P

AN

ELD

ISCU

SSIO

N

9.50 Regulatory Updates and Changes in the Pharmaceutical Sector – What’s New, Trends and Impact• Encouraging innovation and healthy development of the pharmaceutical industry• Recent changes and updates in the pharmaceutical and medical device sectors – What to look out for?• Meeting the growing clinical development demand and addressing approval delays and review process• Enhancing your talent pool with the right experts to spearhead governmental oversight and supervisionModerator: Lin Hong, Associate Director – Regulatory Affairs, Asia Pacific, Russia CIS (APAC) Established Pharmaceuticals, AbbottPanelists: Dr Meir-Chyun Tzou, Senior Researcher & Former Director of Division of Pharmaceutical Affairs, Taiwan Food and Drug Administration (TFDA), TaiwanPA

NEL

DIS

CUSS

ION

China’s Pharmaceutical Market Outlook

10.30 Morning Networking & Refreshment Break

• Choose Your Sessions Across 3 Different Tracks with a GOLD PASS! •

CHINA

11.15Chairperson’s Opening RemarksGu Chengming, Vice President & the head of medical affairsof Pfizer China & the Chairman Medical Affairs Group,RDPAC, China

Chairperson’s Opening RemarksLin Hong, Associate Director – Regulatory Affairs, AsiaPacific, Russia CIS (APAC) Established Pharmaceuticals,Abbott

Chairperson’s Opening RemarksEmmanuel Vignal, Partner, Greater China Leader, FraudInvestigation & Disputes Services, EY

Current Clinical Trial Landscapein Asia

Regulatory Updates to ImproveDrug Approval Timelines

China’s Healthcare Reform &Compliance Frameworks

Execution Gap in Global Drug Development: TheExpectation And Current Position of AsiaDan Paulson, Vice President, Global Clinical Development,Group Head, Cardiometabolism Risk Management andAnti-infectives, Bayer HealthCare Pharmaceuticals,China

Updates and Changes in Pharmaceutical Regulationin TaiwanDr Meir-Chyun Tzou, Senior Researcher & Former Directorof Division of Pharmaceutical Affairs, Taiwan Food andDrug Administration (TFDA)

The ABAC Risk is here to Stay – Key enforcementActions, Trends and Outlook for 2016 for the LifeSciences IndustryEmmanuel Vignal, Partner, Greater China Leader, FraudInvestigation & Disputes Services, EY

Accelerating the Global Drug Developmentin China

Panelists:

Dan Paulson, Vice President, Global Clinical Development,Group Head, Cardiometabolism Risk Management and Anti-infectives, Bayer HealthCare Pharmaceuticals, China

Ye Hua, Senior Vice President, Clinical Development andRegulatory Affairs, Hutchison Medipharma, China

PAN

EL D

ISCU

SSIO

N

E-Labelling & Packaging

Concomitant Review and Assessment of PackageMaterials and ExcipientsMs Yan WANG, Head of Shanghai Food and Drug PackagingMaterial Control Center, Shanghai Municipal Food andDrug Administration (SFDA)

China Health Care Reform – Big Business & Big RiskRobert Youill, Senior Managing Director - Global Risk andInvestigations, FTI Consulting, China

Labelling

2.00

Latest Developments in Smart LabelingFrank Jaeger, Managing Director, Faubel & Co., Germany

Building Compliance TeamsImplementation of an Innovative Labeling Hubin AsiaRie Matsui, Director, Regional Labeling Head for Asia,Pfizer Japan

Building an Effective Compliance Team

12.40 Networking Lunch & Meet With VIP Guests

VIP Table 1: Samantha Du, CEO, Chairman of the Board, Zai Laboratories, ChinaVIP Table 2: Weikang Tao, CEO, R&D Centre, Shanghai Hengrui Medicine, ChinaVIP Table 3: Yin Xiang Wang, CEO, Betta Pharmaceuticals, China

11.30

12.10

CHINA


Best Practices in ClinicalProject Management

PharmacovigilanceData Analytics in Compliance

2.40

PAN

EL D

ISCU

SSIO

N

Navigating the Quality Control of Drugs and Post-Market RegulationMs Yan WANG, Head of Shanghai Food and Drug PackagingMaterial Control Center, Shanghai Food and DrugAdministration (SFDA)

Mitigating Risks and Demonstrating ReturnsThrough Data AnalyticsChi CHEN, Partner, Fraud Investigation & DisputesServices, EY

Differentiating Regulations in Japan, Korea andChina on Postmarketing Drug Special Monitoring

3.20 Afternoon Networking & Refreshment Break

4.00

PAN

EL D

ISCU

SSIO

N

Risk Management Planning to Tackle EthnicDifferencesYu (Vivian) Sun, Associate Director, Safety Surveillance &Risk Management, China Research & Development Center,Pfizer Inc, China

The Compliance Landscapeand Approach in ChinaKaren Eryou, Senior Director, CorporateCompliance APAC, UCB, China

4.40

Collaboration Tactics and Organizational Strategiesfor Effective Clinical Trial BudgetingPanelists:Wang Xiao Mei, Director, Clinical Operations, TenNorTherapeutics, China

Geng Wu, Head of Clinical Project Management China,Development East Asia & Network, UCB, China

Daisuke Yamashita, Associate Director, Strategic ProjectManagement, Takeda Development Centre Shanghai,China

Quality Assurance andAnti-Counterfeiting

Building a Quality Culture – Not just a QualityManagement SystemMagnus Jahnsson, Director Regulatory Affairs,Pharmadule Morimatsu AB

Ensuring Sales, Marketing & DistributionPrograms Comply with Local MarketPracticesLily Dong, Sales Director, AstraZeneca, China

5.30 Chairperson’s Summary of the Day & End of Conference Day One

CONFERENCE DAY TWO WEDNESDAY 30 MARCH 20168.30 Morning Networking & Refreshment Break

• Choose Your Sessions Across 3 Different Tracks with a GOLD PASS! •

CHINA

8.55 Chairperson’s Opening RemarksYi Yang, Director, ASO (Internal Medicine), USPharmacovigilance, Sanofi, USA

Chairperson’s Opening RemarksMaija Burtmanis, Healthcare Compliance Officer, Asia PacificMedical Sciences, Johnson & Johnson, Singapore

Regional Partnerships andCoordination

9.00

PAN

EL D

ISCU

SSIO

N Driving Resilient Partnerships for GrowthMay Wei Chun Fang, Global Regulatory Strategist,Bayer Healthcare Co Ltd ChinaLin Hong, Associate Director – Regulatory Affairs,Asia Pacific Russia CIS (APAC) EstablishedPharmaceuticals, AbbottYuko Kikuchi, Senior Director – Asia RegulatoryAffairs, Eisai Co Ltd

Third Party Compliance Program AssessmentMasood Ahmed, Vice President, Regional Compliance OfficerAsia & JPAC, Sanofi Group, Singapore

MRCT Guidelines andProduct Development

Keeping Drug Development Lean with InternationalMulti-Centre Clinical Trials (IMCT) GuidelinesMay Wei Chun Fang, Global Regulatory Strategist,Bayer Healthcare Co Ltd China

Choosing the Best ClinicalDevelopment Pathway

Accelerating Biologics Drug Development in ChinaGu Jin Ming, Executive Director, Biopharmaceutical R&D,Shanghai Hengrui Medicine, China

Impact of Recent CFDA Regulation on Cancer DrugDevelopment in China: Stakeholder DiscussionModerator:Li Yan, Vice President, Head Unit Physician, Oncology R&D,GlaxoSmithKline Pharmaceuticals, USAPanelists:Li Xu, Corporate Vice President and Head of Global Oncology,Hengrui Co., ChinaCaichun Zhou, Professor, Shanghai Chest Hospital,ChinaXiao Xu, President and CEO, Acea Co, USA &ChinaHua Mu, SVP, WiXi Apptec, ChinaDajun Yang, President and CEO, Ascentage Pharma,China

PAN

EL D

ISCU

SSIO

N

Fostering an Ethical CultureSteffanie Lim-Ho, VP, Ethics & Compliance,Lilly, China

Transparent & Ethical Practices inLocal Markets

Chairperson’s Opening RemarksLin Hong, Associate Director – Regulatory Affairs, AsiaPacific, Russia CIS (APAC) Established Pharmaceuticals,Abbott

How to Make the Successful Transition fromRegistration Trials to Phase IV Studies?

Moderator:Shell Li, Former Head of Clinical Research, BoehringerIngelheim Pharmaceuticals,Chief Medical Officer, Vice President, Global ClinicalDevelopment, HRYZ Biotech, China

Panelists:Benny Li, Group Chief Medical Officer, HansohPharmaceuticals, China

Cristina Chang, Country Medical Director, Celgene, Taiwan

Yan Gong, Head of Clinical Development and Medical AffairsII, Boehringer Ingelheim Pharmaceuticals, China

CHINA


Medical Device Regulations

Medical Device Regulations Overview in the MainEstablished Markets: EU, USA, Japan, Canada andAustraliaVal Theisz, Director Regulatory Affairs, MedicalTechnology Association of Australia (MTAA)

9.40 Southeast Asia as a Key Platform for theAcceleration of Global Clinical TrialTimelines for Chinese PharmaJeffrey Yablon, Vice President, Business Development,General Manager – Asia, Indipharm, Malaysia

Streamlining RegulatoryPathways & Strategies

Regulation on Fixed-Dose Combinations andCo-Packaged DrugsMay Wei Chun Fang, Global Regulatory Strategist,Bayer Healthcare Co Ltd China

Tone at the Middle and Managing PatientRelationshipRiza Faith Ybanez, Legal and Compliance Head – OncologyAsia Pacific, South Africa, Novartis Asia PacificPharmaceuticals Ptd Ltd, Singapore

10.20 Morning Networking & Refreshment Break

10.50 Clinical Development Pathway in TaiwanNathan Chen, Vice President, Chief MedicalOfficer & Head of Global Medicine Development,OBI Pharma, Taiwan

Best Practice ComplianceStrategies & Programs

Leapfrogging the Life-Cycle ManagementRegulatory Pathways: How Efficient Can We Get?Yuko Kikuchi, Senior Director – Asia Regulatory Affairs,Eisai Co Ltd Internal Compliance Program Assessment

Jill Dailey, Assistant General Counsel, Asia Pacific ComplianceLead, Pfizer, US

Strategic Partnerships &Clinical Outsourcing

PAN

EL D

ISCU

SSIO

N

11.40

Implementing Global Strategic Partnerships on aRegional Level: Shaping the Future of Fast and Cost-Effective Clinical Trials in China

Dejun Tang, Head, Analytics, Integrated InformationSciences China, Novartis, China

Christina Bodurow, Senior Director, External Sourcing,Development Center of Excellence, Eli Lilly and Co, USA

Yi Yang, Director, ASO (Internal Medicine), USPV, Sanofi,USA

Tracking Drug Approval Timelines – Getting it Rightat Initial Regulatory Submissions

Ensuring Compliance During Business DevelopmentTransactions & PartnershipKaren Choi, Compliance Director / Corporate Compliance,Pfizer, Korea

12.10 Networking Lunch & Meet With VIP Guests

VIP Table 1: Christina Bodurow, Senior Director, External Sourcing, Development Center of Excellence, Eli Lilly and Co, USAVIP Table 2: Yi Yang, Director, ASO (Internal Medicine), US Pharmacovigilance, Sanofi, USAVIP Table 3: Shell Li, Chief Medical Officer, Vice President, Global Clinical Development, HRYZ Biotech, China

Good Clinical Practice (GCP)and Site ManagemenT

1.30 Exploring Evolving Partnership Models and CROSelection Considerations in ChinaChristina Bodurow, Senior Director, External Sourcing,Development Center of Excellence, Eli Lilly and Co, USA

FDA 505(b)(2) Pathway For New Drug ApplicationLingyan Li, Project Manager – Senior Pharmaceutical AffairsScientist, Tasly Holding Group

How are Compliance Programs Evolving in China vsthe Region?

2.10

Leveraging the Sponsor Relationship Between KOLand Sites for Successful Trials in ChinaYi (Gloria) Wang, Chief China Medical Development andMedical Monitor Asia, United Therapeutics, China

E-CTDs and Dossier Submissions

Risk ManagementAcross Functions

Common Legal Issues and Risk Mitigation with ThirdPartiesTom Chan, Head of Legal Greater China, Takeda (China)Holdings Co. Ltd, China

3.10 Afternoon Networking & Refreshment Break

3.20

Clinical Data Quality

Quality Assurance Measures and Compliance inTrials: Ensuring Inspection Readiness Across MultipleTrial Sites

Liping Zhou, Global Inspection Manager, R&D Quality,Bayer HealthCare, China

Guoying Cao, Director of GCP Office, Huashan Hospital,Fudan University, China

Tackling E-CTDs and Dossiers amidst ChangingRegulatory DevelopmentsJannie Ren, Director – China Head of PPLS (Publishing &Product License Support), Pfizer Regulatory Operation

Coordinating Risk ManagementAcross Functions

Coordinating Risk Management Across FunctionsMaija Burtmanis, Healthcare Compliance Officer, Asia PacificMedical Sciences, Johnson & Johnson, Singapore

4.00

Improved Processes and Vendor Oversight for ClinicalTrials in China: Ensuring Quality, Compliance andROI for Outsourced Trials

Intellectual PropertyLaws & Legal Issues

IP and Patent LitigationSow Wei Wong, Legal Counsel, Takeda Global Research& Development Centre (Asia), Singapore

4.45 Chairperson’s Summary of the Day & End of Conference


CHINA

Co-Located:

CHINA

Early Confirmed Companies Include:


■ China/Hong Kong/Taiwan 60%■ Japan/Korea 5%■ Singapore 10%■ Rest of Asia 10%■ India/Middle East 5%■ Australia/NZ 5%■ US/Europe 5%

■ Pharma/Biopharma 60%■ Government 5%■ CROs 15%■ Legal/Finance/Consultants 5%■ Technology & Solution

Providers 10%■ Research Institutes/Hospitals 5%

Why China isRaiding ForeignCompanies At Dawn

~ Business Insider

Singapore,

January 2015

China's rigidregulations hamperbio-pharmaceuticalindustry

~ Channel News Asia, July 2015

China'sPharmaceuticalFuture - BothComplex and Growing

~ FDA Voice, June 2015

Navigate through a complex R&D environment?

Seek clarity on pharmaceutical regulations anddrug approvals in China?

Ensure your organization is operating compliantly?

Areyou

lookingto:

Areyou

lookingto:

If you answered yes to the above questions, then this conference is for you!The Pharmaceutical Congress (PharmaCon) China brings together a timely platform to explore domestic pharmaceutical

research investments, developments and commercial operations.

WHO SHOULD ATTEND:WHO SHOULD ATTEND:

SPONSORSHIP OPPORTUNITIESWould you like to raise your visibility in China’s pharmaceutical industry industry?Could you benefit from showcasing your products & services before key industry players?Are you seeking the lowest cost way of meeting a target audience of decision-makers?

If so, we can help you achieve your goals! Increase your reach through our extensive marketing campaign, targeted at your qualified business audience.For information about placing your brand & profile top-of-mind to key buyers, contact Yvonne Leong, Business Development Manager ~Tel: +65 6508 2489 or Email: [email protected]

Abbott • Acea Co. • Allergan • Amgen • Astrazeneca • Bayer Healthcare Co Ltd China • Bayer Healthcare

Pharmaceuticals • Biocon • Zhejiang Betta Pharmaceuticals • Boehringer Ingelheim Pharmaceuticals • Bristol-

Myers Squibb • Cardinal Health • Celgene • China Chamber of Commerce for Import and Export of Medicines

and Health Products (CCCMHPIE) • China Pharmaceutical Innovation and Research Development Association

(PhIRDA) • Eisai Co Ltd • Eli Lilly & Co. • Faubel & Co. • Fountain Medical Development • FTI Consulting •Fudan University • GEC Risk Advisory LLC • GlaxoSmithKline Pharmaceuticals • Hengrui Co. • Hua Medicine

• Hutchison Medipharma • HYRZ Biotech • Indian Society for Clinical Research • Indipharm • Janssen

Pharmaceuticals • Johnson & Johnson • Jones Day • Lilly China • Medical Technology Association of Australia

(MTAA) • Novartis Pharmaceuticals (China) • Novartis Asia Pacific Pharmaceuticals • Novo Nordisk (China)

Pharmaceutical Co., Ltd • NUS East Asian Institute (EAI) • OBI Pharma Inc • PAREXEL International • Peking

University Health Science Center • Pfizer (China) Research & Development Co Ltd Center • Pharmadule Morimatsu

AB • R&G PharmaStudies • RDPAC • Sanofi-Aventis • SciClone Pharmaceuticals • Shanghai Chest Hospital

• Shanghai Food and Drug Administration (SFDA) • Shanghai Hengrui Pharmaceuticals • Shenzhen Chipscreen

Biosciences • TaiGen Biotechnology • Taiwan Food and Drug Administration (TFDA) • Takeda (China) Holdings

• Takeda Global Research & Development Centre (Asia) Pte Ltd • Takeda Pharmaceuticals • Tasly Holding

Group • TenNor Therapeutics • UCB • US China Anti-Cancer Association • United Therapeutics • Zai Laboratories

Plus many more...

[email protected]

Fax+65 6508 2407

Customer Service Hotline+65 6508 2401

Webwww.pharmaconchina.com

DATA PROTECTION

CANCELLATIONS / SUBSTITUTION

IMPORTANT NOTE

REG

NO. 2

0010

8203

N

• Payment by bankers draft or cheque in S$ or US$ should bemade in favour of “IBC Asia (S) Pte Ltd” and mailed to:IBC Asia (S) Pte Ltdc/o Informa Regional Business Services111 Somerset Road, TripleOne Somerset #10-05Singapore 238164Attn: The Accounts Receivable Team

• Payment by bank transfer in S$ or US$ made payable to:IBC Asia (S) Pte LtdA/C No.:147-059513-001 (S$)A/C No.:260-457866-178 (US$)The Hongkong and Shanghai Banking Corporation Limited21 Collyer Quay, HSBC BuildingSingapore 049320Bank Swift Code: HSBCSGSGBank Code: 7232

• Payment by Credit Card (AMEX, VISA or MasterCard).The best way to pay by credit card is through our secureportal built into the website. To pay by phone please indicatethe contact name and details below and our CustomerServices Team will call within 24 hours to take payment.Please do not send credit card information by email.

The personal information entered during your registration/order,or provided by you, will be held on a database and may beshared with companies in the Informa Group in the UK andinternationally. Occasionally, your details may be obtained fromor shared with external companies who wish to communicatewith you offers related to your business activities. If you do notwish your details to be used for this purpose, please contactour Database Department at Email: [email protected],Tel: +65 6508 2400 or Fax: +65 6508 2408.

Should you be unable to attend, a substitute delegate iswelcome at no extra charge. Cancellations must be received inwriting at least 10 business days before the start of the event,to receive a refund less 10% processing fee per registration.The company regrets that no refund will be made available forcancellation notifications received less than 10 business daysbefore the event.

Please quote the name of the delegate, event title and invoicenumber on the advice when remitting payment. Bank chargesare to be deducted from participating organisations own accounts.Please fax your payment details (copy of remittance advice,cheque or draft to +65 6508 2407).Attendance will only be permitted upon receipt of full payment.Participants wishing to register at the door are responsible toensure all details are as published. IBC assumes no furtherliability or obligation, beyond the refund of the paid registrationfee, in the event of postponement or cancellation by IBC.

5 EASY WAYS TO REGISTER

RESERVE YOUR PLACE TODAY!

CREDIT CARD PAYMENTSThe best way to pay by credit card is through our secure on-line registration process, simply log on to the website atwww.pharmaconchina.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact nameand details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in thestrictest confidence, please do not send payment details by email.

Department:

Email:

■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd■ I am paying by bank transfer (copy attached)■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)

PAYMENT METHOD(Please tick)

Early Bird RateRegister & pay on orbefore 8 Jan 2016

Special RateRegister & pay on orbefore 26 Feb 2016

Normal RateRegister & pay after

26 Feb 2016FEE PER DELEGATE

❑ 2-Day Package USD 1,695 USD 1,895 USD 2,095 USD 2,295

DELEGATE 1 DETAILS

HOTEL INFORMATION

Grand Hyatt Shanghai, ChinaJin Mao Tower, 88 Century Boulevard Pudong, Shanghai 200121Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381 Contact Person: April GuEmail: [email protected]

PAYMENT TERMSPayment must be received 10 business days prior to the event. To take advantage of discounts with an expiry date, registration and payment must be received by the cut-off date.

INTERNATIONAL COMPANIES – Global Headquarters Located Outside of Mainland China

DOMESTIC CHINA COMPANIES – Global Headquarters Located within Mainland China

GOLD PASS: Add USD 150 / CNY 1000 to upgrade to Gold Pass and have access to all 3 conferences.

Super Early BirdRegister & pay on orbefore 27 Nov 2015

CNY 5,000 CNY 6,000 CNY 7,000 CNY 8,000

MAIL the attached registration form with yourcheque toIBC Asia (S) Pte Ltdc/o Informa Regional Business Services111 Somerset Road,TripleOne Somerset #10-05,Singapore 238164

Name: Dr/Mr/Ms

Job Title:

Department:

Tel: Mobile No.:

Email:

Who is Head of your Department? Who is Head of Training?

Please photocopy for additional delegates

Credit card contact:

Direct phone number:

+65 6508 2401 [email protected] www.pharmaconchina.com

CHINA

■ Yes! I/We will attend the Pharmacon China • 29 – 30 March 2016, Grand Hyatt Shanghai, China■ Clinical Trials China ■■ Pharmaceutical Regulatory Summit China ■■ Pharmaceutical Compliance■ GOLD PASS (All 3 Events)

❑ 2-Day Package

❑

Co-located events:

DELEGATE 2 DETAILS

Name: Dr/Mr/Ms

Job Title:

Department:

Tel: Mobile No.:

Email:

Main Business/Activity:

Postal Code:

Who is Head of your Department? Who is Head of Training?

Company Name:

Address:

REGISTER TODAY!


CHINA

Pharmaceutical Congress China 29-30 March 2016

Science

Transcript of Pharmaceutical Congress China 29-30 March 2016